Patents Assigned to Seattle Children's Hospital
-
Publication number: 20210370037Abstract: Transcutaneous, ultrasound-mediated methods for administering compound(s) to subject tissue(s) are provided. Examples involve positioning an occluding device in a vessel such that the blockage is adjacent to target tissue; engaging the device to occlude outflow from a region adjacent to the tissue; administering compound(s) to the vessel such that it is substantially retained adjacent to the target tissue; determining the location of the compound and/or a detectable adjunct compound optionally administered with the compound, using diagnostic ultrasound, radiography, or fluorography; administering therapeutic ultrasound energy transcutaneously to mediate delivery of the compound across the vessel wall and into adjacent target tissue.Type: ApplicationFiled: April 26, 2019Publication date: December 2, 2021Applicant: Seattle Children's Hospital D/B/A Seattle Children's Research InstituteInventors: Carol Hsing Miao, Feng Zhang
-
Publication number: 20210353731Abstract: The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.Type: ApplicationFiled: February 1, 2021Publication date: November 18, 2021Applicant: SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTEInventors: Ashley M. Vaughan, Stefan H.I. Kappe, Dorender A. Dankwa
-
Publication number: 20210348195Abstract: Artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types are described. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in GABAergic interneurons.Type: ApplicationFiled: October 3, 2019Publication date: November 11, 2021Applicants: Allen Institute, Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Jonathan Ting, Boaz P. Levi, John K. Mich, Edward Sebastian Lein, Franck Kalume
-
Publication number: 20210341492Abstract: Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease is described. The newborn screening can detect these disorders from dried blood spots already routinely collected at the time of birth. Early detection of these disorders will greatly improve patient outcome as each of them can be fatal once symptoms emerge.Type: ApplicationFiled: October 4, 2019Publication date: November 4, 2021Applicants: Seattle Children's Hospital d/b/a Seattle Children's Research Institute, Fred Hutchinson Cancer Research CenterInventors: Sihoun Hahn, Sunhee Jung, Jeffrey Whiteaker, Troy Torgerson, Amanda Paulovich, Christopher Collins, Remwilyn Dayuha
-
Patent number: 11160833Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.Type: GrantFiled: September 22, 2020Date of Patent: November 2, 2021Assignees: The Regents of the University of California, Seattle Children's HospitalInventors: Yvonne Y. Chen, Eugenia Zah, Michael C. Jensen
-
Patent number: 11155616Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient.Type: GrantFiled: February 27, 2019Date of Patent: October 26, 2021Assignee: Seattle Children's HospitalInventor: Michael C. Jensen
-
Publication number: 20210309740Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.Type: ApplicationFiled: September 29, 2020Publication date: October 7, 2021Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventor: Michael Jensen
-
Publication number: 20210302435Abstract: Early detection of lysosomal storage diseases (LSDs) including Mucopolysaccharidosis Type I (MPS I) and Pompe Disease can greatly improve patient outcome as each disease can be fatal once symptoms emerge. Screening for MPS I and Pompe Disease using biological samples including dried blood spots (DBS), buccal swab, peripheral blood mononuclear cells (PBMCs), or white blood cells (WBCs) is described. The disclosed methods and assays provide a robust way to screen newborns for LSDs. The disclosed methods and assays can also allow rapid prediction of whether a patient with LSD will develop an immune response to enzyme replacement therapy (ERT), thus improving treatment for patients with LSDs. The disclosed methods and assays can also further reduce the number of false positives caused by pseudo deficiency cases of LSD, such as MPS I and Pompe Disease.Type: ApplicationFiled: March 31, 2021Publication date: September 30, 2021Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Sihoun Hahn, Christopher Collins, Remwilyn Dayuha, Fan Yi
-
Patent number: 11123369Abstract: Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.Type: GrantFiled: November 3, 2020Date of Patent: September 21, 2021Assignee: Seattle Children's HospitalInventor: Michael C. Jensen
-
Publication number: 20210285965Abstract: Clinical diagnosis and newborn screening for primary immunodeficiencies (PIDDs) is described. The PIDDs include X-linked chronic granulomatous disease (X-CGD), X-linked lymphoproliferative syndrome (XLP1; SH2D1A deficiency), familial hemophagocytic lymphohistiocytosis 2 (FHL2), ataxia telangiectasia (AT), common variable immunodeficiency (CVID; B-cell dysfunctions), severe combined immunodeficiency (SCID), adenosine deaminase (ADA) deficiency, and dedicator of cytokinesis 8 (DOCKS) deficiency. Additionally, cell specific markers for platelets (CD42), natural killer (NK) cells (CD56), and T cells (CD3epsilon and CD3delta) can be used as secondary markers to provide support for diagnosis of disease.Type: ApplicationFiled: March 3, 2021Publication date: September 16, 2021Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Sihoun Hahn, Christopher Collins, Remwilyn Dayuha, Fan Yi
-
Publication number: 20210269772Abstract: Described herein is a reversible aptamer selection technology for production-scale isolation of label-free cells (e.g., CD8+ T cells). Provided herein are methods for isolating a cell of interest from a biological sample by contacting the biological sample with an aptamer that specifically binds a cell surface marker specific for the cell of interest; separating the aptamer-bound cells from cells not bound to the aptamer; and recovering a cell of interest by disrupting binding of the aptamer to the cell surface marker.Type: ApplicationFiled: July 16, 2019Publication date: September 2, 2021Applicants: UNIVERSITY OF WASHINGTON, SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTEInventors: Suzie H. PUN, Michael JENSEN, Nataly KACHEROVSKY, Ian CARDLE
-
Patent number: 11105802Abstract: The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.Type: GrantFiled: December 10, 2013Date of Patent: August 31, 2021Assignees: SEATTLE CHILDREN'S HOSPITAL, The University of QueenslandInventors: Yadveer Grewal, Gerard A. Cangelosi, Muhammad J. A. Shiddiky, Matt Trau
-
Publication number: 20210261946Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.Type: ApplicationFiled: April 29, 2021Publication date: August 26, 2021Applicant: SEATTLE CHILDREN'S HOSPITAL (dba SEATTLE CHILDREN'S RESEARCH INSTITUTE)Inventors: Andrew M. SCHARENBERG, Michael T. CERTO, Kamila Sabina GWIAZDA
-
Publication number: 20210254043Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.Type: ApplicationFiled: April 29, 2021Publication date: August 19, 2021Applicant: SEATTLE CHILDREN'S HOSPITAL (dba SEATTLE CHILDREN'S RESEARCH INSTITUTE)Inventors: Andrew M. SCHARENBERG, Michael T. CERTO, Kamila Sabina GWIAZDA
-
Publication number: 20210228742Abstract: Methods, compositions, and systems for treating subject(s) in need of plasma Factor VIII, particularly a subject having preexisting anti-FVIII inhibitory antibodies, are provided. The methods involve administering to the subject a therapeutically effective amount of an inflammation suppressor, a therapeutically effective amount of a CD8+ T cell depleting agent, and a therapeutically effective amount of a composition comprising a lentiviral vector (LV) comprising an optimized FVIII expression cassette expressibly linked to a megakaryocyte-specific promoter. Such methods, compositions, and systems are useful to treat subjects with blood clotting disorder(s), such as hemophilia A.Type: ApplicationFiled: April 26, 2019Publication date: July 29, 2021Applicant: Seattle Children's Hospital D/B/A Seattle Children's Research InstituteInventors: Carol Hsing MIAO, David J. RAWLINGS, Chong LI
-
Publication number: 20210186426Abstract: Examples of systems and methods described herein may estimate a state of the ear canal of a patient utilizing a smart phone by characterizing acoustic waveforms reflected off the patient's eardrum. Examples may include an acoustic focusing apparatus that may be connected to a smart phone to provide acoustic signals to and receive reflected signals from an ear canal.Type: ApplicationFiled: September 6, 2019Publication date: June 24, 2021Applicants: University of Washington, Seattle Children's Hospital (DBA Seattle Children's Research Institute)Inventors: Sharat Raju, Shyamnath Gollakota, Justin Chan, Randall Bly, Rajalakshmi Nandakumar
-
Patent number: 10960065Abstract: The invention provides compositions and methods for preventing or reducing the severity of malaria.Type: GrantFiled: February 22, 2019Date of Patent: March 30, 2021Assignees: Rhode Island Hospital, Seattle Children's HospitalInventors: Jonathan Kurtis, Christian Parcher Nixon, Dipak Kumar Raj, Jennifer Frances Friedman, Michal Fried, Patrick Emmet Duffy
-
Patent number: 10919950Abstract: The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.Type: GrantFiled: January 10, 2017Date of Patent: February 16, 2021Assignee: Seattle Children's HospitalInventors: Michael C. Jensen, Adam Johnson
-
Publication number: 20210015898Abstract: Selectively providing voltage-gated sodium channel function sufficient to rescue impaired Nav1.1 function to inhibitory neurons is described. Provided voltage-gated sodium channel function sufficient to rescue impaired Nav1.1 function in inhibitory neurons can be used to treat disorders such as epilepsy, and more particularly, Dravet Syndrome.Type: ApplicationFiled: April 9, 2019Publication date: January 21, 2021Applicants: ALLEN INSTITUTE, SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTEInventors: John K. Mich, Edward Sebastian Lein, Jonathan Ting, Boaz P. Levi, Erik Hess, Franck Kalume
-
Patent number: 10869889Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.Type: GrantFiled: October 18, 2019Date of Patent: December 22, 2020Assignees: Fred Hutchinson Cancer Research Center, Seattle Children's HospitalInventors: Michael C. Jensen, Stanley R. Riddell, Michael Hudecek